[Retracted] Silencing NOB1 enhances doxorubicin antitumor activity of the papillary thyroid carcinoma in vitro and in vivo.

Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that certain of the western blotting assay data shown in Figs. 2 and 5, and the tumour images shown in Fig. 6A, were strikingly similar to data appearing in different form in other articles by different authors. Owing to the fact that the contentious data in the above article had already been published elsewhere, or were already under consideration for publication, prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in Oncology Reports 33: 1551-1559, 2015; DOI: 10.3892/or.2015.3730].

Pediatric differentiated thyroid carcinoma: The clinicopathological features and the coexistence of Hashimoto's thyroiditis.

BACKGROUND/OBJECTIVE: The purpose of this study is to assess outcomes and the detailed clinicopathological features of differentiated thyroid carcinoma (DTC), including the relation of Hashimoto's thyroiditis and postoperative pathological features in child under 18 years old. METHODS: We reviewed patients with DTC under 18 years old (pediatric DTC patients) seen during recent 16 years. The clinicopathological features and outcomes of pediatric DTC were analyzed by comparison with patients of 19-20 years old or 21-44 years old. RESULTS: Sixty four children with DTC [median age 16 years (range, 5-18)] were studied. The ratio of female to male was 5:1, but no difference was found by comparison with adult of 21-44 years old. No difference was found in multifocality, but DTC in child showed lager tumor size (P < 0.001), higher rate of extrathyroidal extension (P = 0.017), more local or pulmonary metastasis (P < 0.001, P < 0.001 respectively) than adult thyroid carcinoma. High rate of Hashimoto's thyroiditis (19/43) without influence on pathological features was found in patients under 18 years old. No differences, except for distant metastasis, were found by comparison of clinicopathological features between patients under 18 years old and 19-20 years old. Pediatric patients possessed highest rates of persistent/recurrent disease, though only one child died. CONCLUSION: Pediatric DTC has more aggressive behavior characterized by a high rate of extrathyroidal extension, local and pulmonary metastasis. Pediatric DTC has low mortality, but active treatments are needed for the high risk of persistent or recurrent diseases. Hashimoto's thyroiditis may be associated with the pathogenesis or mechanism of pediatric DTC.

Silencing NOB1 enhances doxorubicin antitumor activity of the papillary thyroid carcinoma in vitro and in vivo.

Doxorubicin (DOX), a broad­spectrum anthra-cyclin, is in wide clinical use for the treatment and prevention of thyroid cancer. However, the effectiveness of the treatment remains limited due to inherent tumor resistance to DOX. Results of a previous study demonstrated that downregulation of NIN1/RPN12 binding protein 1 homolog (NOB1) expression via adenovirus expression vector carrying NOB1 siRNA (Ad/sh-NOB1) induced cancer apoptosis and increased the radiosensitivity of papillary thyroid carcinoma (PTC) cells. However, whether knockout NOB1 can decrease DOX resistance remains unclear. Therefore, in the present study, the effect of Ad/sh-NOB1 infection, independently or in combination with DOX, was determined in a PTC cell line to identify more effective therapeutics against PTC cancer. Furthermore, tumor growth ability in nude mice was determined to identify the combination treatment effect in tumorigenesis in vivo. The results showed that Ad/sh-NOB1 combined with DOX treatment in PTC cells significantly suppressed proliferation, colony formation, migration and invasion, and induced cell apoptosis and arrest in the G0/G1 stage as compared to Ad/sh-NOB1 or DOX monotherapy. We also found that this combination suppressed the tumor growth of a nude mouse model as compared to Ad/sh-NOB1 or DOX monotherapy. In addition, Ad/sh-NOB1 combined with DOX treatment significantly increased activation of the p38 MAPK pathway, which may contribute to inhibition of PTC cell growth and decreased DOX resistance. Taken together, the experimental results indicate that Ad/sh-NOB1 combined with DOX treatment is a potential drug candidate for the treatment of papillary thyroid carcinoma.